Tango Therapeutics (TNGX) Capital Expenditures Growth (1y) (2021 - 2026)
Tango Therapeutics (TNGX) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 143.40% |
| 10 | Tango Therapeutics | 3.86 Bn | 3.70 Bn | - | -119.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.61% |
| Dec 31, 2025 | -90.23% |
| Sep 30, 2025 | 84.70% |
| Jun 30, 2025 | -53.64% |
| Mar 31, 2025 | 245.71% |
| Dec 31, 2024 | 162.44% |
| Sep 30, 2024 | -3,531.25% |
| Jun 30, 2024 | -17.17% |
| Mar 31, 2024 | -105.65% |
| Dec 31, 2023 | -221.23% |
| Sep 30, 2023 | -99.76% |
| Jun 30, 2023 | 230.71% |
| Mar 31, 2023 | 24.00% |
| Dec 31, 2022 | 495.82% |
| Sep 30, 2022 | 1,448.60% |
| Jun 30, 2022 | -185.39% |
| Mar 31, 2022 | 203.03% |
| Dec 31, 2021 | -123.93% |